Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cinacalcet
Drug ID BADD_D02434
Description Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.
Indications and Usage For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
Marketing Status approved
ATC Code H05BX01
DrugBank ID DB01012
KEGG ID D03504
MeSH ID D000069449
PubChem ID 156419
TTD Drug ID D03YGR
NDC Product Code 72865-150; 72865-151; 72865-152; 42291-459; 65862-832; 16714-080; 42291-461; 67877-504; 68180-228; 42543-962; 47335-600; 51407-297; 63629-8765; 63629-8764; 63629-9607; 64380-885; 67877-503; 69097-410; 69097-412; 47335-380; 50268-153; 51407-296; 76282-674; 76282-675; 16729-440; 16729-441; 31722-104; 65162-155; 65162-213; 67877-505; 42291-460; 42543-961; 43598-368; 65162-157; 65862-831; 69097-411; 43598-369; 63629-8763; 63629-9606; 63629-9608; 65862-833; 68180-226; 31722-103; 47335-379; 60687-525; 64380-883; 68180-227; 76282-676; 0904-7067; 31722-105; 43598-367; 64380-884; 16729-442; 42543-963; 51407-295
UNII UAZ6V7728S
Synonyms Cinacalcet | Cinacalcet Hydrochloride | Alpha-methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethanamine, (alphaR)-hydrochloride | Sensipar | AMG 073 | KRN 1493 | AMG073
Chemical Information
Molecular Formula C22H22F3N
CAS Registry Number 226256-56-0
SMILES CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood disorder01.05.01.0040.002306%Not Available
Adverse drug reaction08.06.01.0090.758755%Not Available
Bone lesion15.02.04.0160.000391%Not Available
Drug intolerance08.06.01.0130.056017%Not Available
Nasal disorder22.04.03.0040.000860%Not Available
Unevaluable event08.01.03.0510.216368%Not Available
Peripheral arterial occlusive disease24.04.03.0100.000586%Not Available
Arterial occlusive disease24.04.02.0210.000860%Not Available
High turnover osteopathy15.02.03.011; 20.01.01.009; 14.04.04.0110.000782%Not Available
Effusion08.01.03.0520.000391%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.153393%Not Available
Skin haemorrhage24.07.01.103; 23.06.07.0010.001994%Not Available
Iron overload14.13.03.002; 12.02.08.0050.000391%
Thyroid cancer16.24.03.001; 05.02.05.0010.000977%Not Available
Pharyngeal disorder22.04.05.0070.001525%Not Available
Adverse reaction08.06.01.0180.010555%Not Available
Oral disorder07.05.01.0050.002189%Not Available
Gastrointestinal sounds abnormal07.01.01.0020.001994%Not Available
Brown tumour14.04.04.010; 20.01.01.008; 15.02.03.0100.001055%Not Available
Gastrointestinal tract irritation07.08.03.0080.001720%Not Available
Hyperparathyroidism tertiary14.04.01.023; 05.04.01.0060.000391%Not Available
Monocytopenia01.02.02.0050.000391%Not Available
Obstruction gastric07.13.04.0020.000391%
Pancreatitis relapsing07.18.01.0110.000391%Not Available
Recurrent cancer16.16.01.0150.000391%Not Available
Laziness19.04.04.0050.001994%Not Available
Hungry bone syndrome05.04.03.004; 15.02.03.015; 14.04.04.0140.001368%Not Available
Multimorbidity08.01.03.0750.000391%Not Available
Heart valve incompetence02.07.02.0030.000782%Not Available
Internal haemorrhage24.07.01.0720.001368%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages